- Head of country’s vaccine task force says poor countries will be given financial help to buy drugs that will prove to be a ‘global public good’
- Executive from state-owned drug maker Sinopharm offers safety assurances and says ‘several dozen countries’ are interested in firm’s vaccine
Health officials and executives from pharmaceutical companies also vouched for the safety record so far of Chinese-made vaccines at a press conference on Tuesday.
China is a leader in Covid-19 vaccine development, producing four of the 11 candidate vaccines that are undergoing stage three clinical trials, including one from state-owned Sinopharm.
Despite concerns over the quality of the country’s vaccines due to high-profile safety scandals in the past, Sinopharm chairman Liu Jingzhen, told the event that “several dozen countries” had expressed interest in the company’s products.
“When Chinese vaccines are successfully developed and launched, they will become a global public good. Therefore, when we are offering vaccines globally, we will also set a fair and reasonable price,” said Zheng Zhongwei, who heads the National Health Commission’s vaccine development task force.
source:SCMP
